We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+119.85%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$242M
AUM Growth
+$88.7M
Cap. Flow
-$51.4M
Cap. Flow %
-21.19%
Top 10 Hldgs %
63.25%
Holding
38
New
12
Increased
4
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$16.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14M
3
APGE icon
Apogee Therapeutics
APGE
+$11.6M
4
NKTR icon
Nektar Therapeutics
NKTR
+$9.93M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$6.79M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$70M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$20.5M
3
LEGN icon
Legend Biotech
LEGN
+$8.73M
4
AKBA icon
Akebia Therapeutics
AKBA
+$7.23M
5
EOLS icon
Evolus
EOLS
+$6.63M

Sector Composition

Rank Sector Weight
1 Healthcare 98.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
1
Amylyx Pharmaceuticals
AMLX
$2.05B
$23.1M 9.53%
1,700,000
-300,000
-15% -$2.82M
RZLT icon
2
Rezolute
RZLT
$480M
$23M 9.5%
2,451,809
-581,653
-19% -$3.87M
NKTR icon
3
Nektar Therapeutics
NKTR
$2.39B
$17.1M 7.04%
+300,000
New +$9.93M
ZURA icon
4
Zura Bio
ZURA
$497M
$16.5M 6.81%
3,815,930
+645,736
+20% +$1.16M
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$15.2M 6.27%
+225,000
New +$16.7M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$14.9M 6.15%
+75,000
New +$14M
ABVX
7
Abivax
ABVX
$11B
$12.7M 5.25%
150,000
-1,141,617
-88% -$70M
APGE icon
8
Apogee Therapeutics
APGE
$10.2B
$12.1M 4.98%
+304,000
New +$11.6M
DNTH icon
9
Dianthus Therapeutics
DNTH
$5.68B
$10.5M 4.31%
+265,803
New +$6.79M
CYTK icon
10
Cytokinetics
CYTK
$11B
$8.24M 3.4%
150,000
– –
IMVT icon
11
Immunovant
IMVT
$8.09B
$8.06M 3.32%
500,000
+237,824
+91% +$3.85M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.32B
$8.03M 3.31%
200,000
– –
NGNE icon
13
Neurogene
NGNE
$696M
$7.74M 3.19%
446,814
-39,045
-8% -$784K
EPRX
14
Eupraxia Pharmaceuticals
EPRX
$380M
$7.08M 2.92%
+1,200,000
New +$6.53M
UPB
15
Upstream Bio Inc
UPB
$349M
$5.64M 2.33%
300,000
– –
JBIO
16
Jade Biosciences
JBIO
$1.22B
$5.46M 2.25%
632,599
+134,545
+27% +$1.1M
IONS icon
17
Ionis Pharmaceuticals
IONS
$9.35B
$5.23M 2.16%
80,000
-420,000
-84% -$20.5M
AKRO
18
DELISTED
Akero Therapeutics
AKRO
$4.93M 2.03%
103,848
– –
TSHA icon
19
Taysha Gene Therapies
TSHA
$1.59B
$4.91M 2.02%
1,500,000
– –
CNTX icon
20
Context Therapeutics
CNTX
$56.4M
$4.54M 1.87%
4,683,711
– –
PHVS icon
21
Pharvaris
PHVS
$2.39B
$3.87M 1.6%
+155,105
New +$3.44M
DBVT
22
DBV Technologies
DBVT
$807M
$3.79M 1.56%
378,594
+3,915
+1% +$38.1K
LEGN icon
23
Legend Biotech
LEGN
$4.3B
$3.7M 1.53%
113,460
-236,540
-68% -$8.73M
ORKA
24
Oruka Therapeutics
ORKA
$5.56B
$3.53M 1.45%
+183,330
New +$2.72M
UNCY icon
25
Unicycive Therapeutics
UNCY
$148M
$3.47M 1.43%
796,558
– –
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Great Point Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Great Point Partners held 38 positions worth $242M, up 58% from $154M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Great Point Partners withdrew a net $51.4M in Q3 2025, closing 8 positions and reducing 6 holdings. Its most notable exit was Akebia Therapeutics, an estimated $7.23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Soleno Therapeutics worth $15.2M.

  • Great Point Partners's largest Q3 2025 buy was Soleno Therapeutics: 225,000 shares worth $15.2M.
  • Great Point Partners added most to Immunovant in Q3 2025, an estimated $3.85M increase.
  • Great Point Partners's biggest Q3 2025 reduction was Abivax, cutting an estimated $70M.
  • Great Point Partners fully exited Akebia Therapeutics in Q3 2025, selling an estimated $7.23M.
  • Great Point Partners's ten largest holdings make up 63% of its $242M portfolio in Q3 2025.
  • Great Point Partners opened 12 new positions and closed 8 in Q3 2025.
  • Great Point Partners's portfolio value rose 58% quarter-over-quarter to $242M.

Based on Great Point Partners's 13F filing for Q3 2025, filed 14 Nov 2025.